Introduction: A revolutionary stride has been made in the field of genetic engineering, as researchers from the University of Trento introduce a novel CRISPR enzyme, CoCas9, which promises to enhance the delivery and efficacy of in vivo gene therapy using...
Regeneron Pharmaceuticals Inc. and Mammoth Biosciences Inc., have joined forces to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. Regeneron is developing adeno-associated viral vectors (AAVs) using...
CRISPR pioneer Jennifer Doudna, Ph.D., looks set to continue to push the boundaries of gene editing, as she announces plans to team up with life sciences giant Danaher to create a center focused on generating new therapies for rare and other diseases. The center,...
On December 8, 2023, the U.S. Food and Drug Administration (FDA) approved two innovational gene therapies, Casgevy and Lyfgenia, for treating sickle cell disease (SCD) in patients aged 12 and older. This marks the first approval of cell-based gene therapies for SCD,...
Days away from an FDA decision on a sickle cell gene therapy, CRISPR Therapeutics is ditching its “first-generation” allogeneic CAR-T candidates and expanding into autoimmune disease. The pipeline update is the latest internal changes to come to the surface at the...
